Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bastholt

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
Melanoma Research|January 21, 2015
MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherinMarie L Bønnelykke-Behrndtz, Torben Steiniche, Tine E Damsgaard, et al.
European Thyroid Journal|November 16, 2016
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid CancerLars Bastholt, Michael C Kreissl, Dagmar Führer, et al.
The American Journal of Dermatopathology|March 29, 2017
Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With UlcerationMarie L Bønnelykke-Behrndtz, Torben Steiniche, Peter Nørgaard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 7, 2022
The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanomaJesper A S Andersen, Anders D Spatzek, Mie H Vilstrup, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2026
Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200]Rasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, et al.
Thyroid : Official Journal of the American Thyroid Association|November 5, 2014
Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohortStefano Christian Londero, Annelise Krogdahl, Lars Bastholt, et al.
Cancer Epidemiology|August 19, 2014
Completeness and validity in a national clinical thyroid cancer database: DATHYRCAStefano Christian Londero, Jes Sloth Mathiesen, Annelise Krogdahl, et al.
Lancet (London, England)|September 27, 2003
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trialJens Overgaard, Hanne Sand Hansen, Lena Specht, et al.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanomaRikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
Melanoma Research|January 21, 2015
MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherinMarie L Bønnelykke-Behrndtz, Torben Steiniche, Tine E Damsgaard, et al.
European Thyroid Journal|November 16, 2016
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid CancerLars Bastholt, Michael C Kreissl, Dagmar Führer, et al.
The American Journal of Dermatopathology|March 29, 2017
Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With UlcerationMarie L Bønnelykke-Behrndtz, Torben Steiniche, Peter Nørgaard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 7, 2022
The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanomaJesper A S Andersen, Anders D Spatzek, Mie H Vilstrup, et al.
European Journal of Cancer (Oxford, England : 1990)|May 21, 2026
Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200]Rasmus Haunstrup Døssing, Elisabeth Hesselberg, Anna Burton Clausen, et al.
Thyroid : Official Journal of the American Thyroid Association|November 5, 2014
Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohortStefano Christian Londero, Annelise Krogdahl, Lars Bastholt, et al.
Cancer Epidemiology|August 19, 2014
Completeness and validity in a national clinical thyroid cancer database: DATHYRCAStefano Christian Londero, Jes Sloth Mathiesen, Annelise Krogdahl, et al.
Lancet (London, England)|September 27, 2003
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trialJens Overgaard, Hanne Sand Hansen, Lena Specht, et al.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanomaRikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, et al.
Pageof 14